Après-demain

Après-demain

Après-demain formalized in 2020 as the single-family office for Switzerland's Mauvernay family, whose wealth originates from Debiopharm — the privately held pharmaceutical company Dr. Rolland-Yves Mauvernay launched in 1979 and that his son Thierry joined in 2001. The firm is structured as the parent for a group now operating across four poles: the original life-science division, a responsible-capital-management arm built in the early 2000s, a philanthropic vehicle launched in 2010, and an impact-oriented division added in 2020 to target climate and social-precarity themes. The investment team allocates across private equity (buyout and growth), private debt (including mezzanine), real estate, secondaries, and fund commitments. Direct co-investment activity is visible in deal consortiums: the firm has backed cybersecurity training platform OffSec alongside Leeds Equity Partners, AI chip developer Tenstorrent with Georgian, and healthcare software company Hoppen alongside Extens and Geneo Capital Entrepreneur. The office also co-founded the Power Sustainable Energy Infrastructure Partnership with Desjardins Group, Great-West Lifeco, and National Bank of Canada, confirming an infrastructure allocation. Geographic exposure spans North America, Europe, Asia, and Oceania. The office operates from a single headquarters in Lausanne. Named deal-side professionals include Private Equity Director Sébastien Beth and Head of Private Debt Jean-Philippe Carvaillo. The team runs parallel tracks for direct investments and fund/co-investment selection, with Joanna Bildstein-Zimmer managing the fund-of-funds sleeve. Thierry Mauvernay simultaneously chairs Romande Energie Holding SA, adding an active-operating-company dimension to the governance model. In December 2024, the firm's LinkedIn listed ten deal professionals covering direct investments, funds, co-investments, and the GeneRActions Planet impact mandate. The structural differentiator is the integration of a revenue-generating life-science operating company under the same family holding. Debiopharm continues to develop oncology and infectious-disease therapies, and its cash flows — combined with an explicit asset-diversification division that predates the family-office entity — give Après-demain a self-funded, non-fundraising posture that can hold assets indefinitely without LP pressure. The parallel philanthropic foundation, Fondation Philanthropique Next, provides a separate channel for mission-related capital.